Clinical trials: Tumor of Prostate
Prostate Cancer
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
The purpose of this study is to evaluate the immune response induced by sipuleucel-T (Provenge®).
- Trial name
- PRIME (NCT01727154)
- Testing
- Sipuleucel-T
- Where
- 39 sites in United States
- Volunteers
- 139 people
- Sponsor
- Dendreon
Adenocarcinoma, Prostate
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
The purpose of this study is to compare the efficacy of three drugs (cyproterone acetate, medroxyprogesterone acetate and venlafaxine) in the treatment of hot flushes caused by leuprorelin LP 11.25 milligram (mg) in participants…
- Trial name
- NCT01011751
- Testing
- Cyproterone acetate, Medroxyprogesterone acetate, Venlafaxine
- Where
- France
- Volunteers
- 311 people
- Sponsor
- Takeda
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Prostate Cancer
Detecting Clinically Significant Prostate Cancer With Advanced MRI Protocols and Extensive Histopathology
In recent years, new and promising approaches have emerged in the field of MRI imaging of the prostate. These approaches usually aim to visualise the so-called "microstructures" of the tissue and are intended to offer greater…
- Trial name
- NCT07432360
- Where
- Brazil
- Volunteers
- 300 people
- Sponsor
- Virdx, Inc.
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
ACCEL is a multicenter, open label phase Ia/Ib/II study of [Ac-225]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Oligometastatic Prostate Carcinoma, Hormone Sensitive Prostate Cancer
- Trial name
- ACCEL (NCT06229366)
- Testing
- [Ac-225]-PSMA-62 (mCRPC), [Ac-225]-PSMA-62 (OmHSPC)
- Where
- 7 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Advanced and/or Metastatic Solid Tumours
Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.
FIH, Phase 1, open-label, multi centre study of CB307, a trispecific Humabody® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours to assess safety and tolerability to determine MTD and preliminary…
- Trial name
- POTENTIA (NCT04839991)
- Testing
- CB307
- Where
- 20 sites in United States, Netherlands and 2 more
- Volunteers
- 70 people
- Sponsor
- Crescendo Biologics Ltd.
Prostate Cancer Metastatic
A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
This study is a multicenter phase I/II study of the treatment of patients with metastatic prostate cancer. The objective of Phase I part is to study the safety and tolerability of LAE001 monotherapy in patients with metastatic…
- Trial name
- NCT03843918
- Testing
- LAE001
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Laekna Limited
Prostate Cancer, Prostate Adenocarcinoma
Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC
Prostate cancer is a leading cause of mortality and morbidity. The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC, T-cells and circulated tumor DNA in prostate cancer…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic
- Trial name
- NCT03494803
- Where
- Kazakhstan
- Sponsor
- HKGepitherapeutics
Bone Neoplasms
Bonefos and the Consumption of Analgesics
The effect of Bonefos on consumption of analgesics (drugs used for pain treatment) in patients with proven bone metastases.
- Trial name
- BICAM (NCT00909142)
- Testing
- Bonefos (Clodronate, BAY94-8393)
- Where
- Czechia
- Volunteers
- 149 people
- Sponsor
- Bayer
Prostate Cancer
Using Virtual Reality (VR) Models for Robotic Prostatectomy - UNC
A prospective, randomized, controlled study designed to assess whether digital virtual reality (VR) models, created from existing CT scans and MRIs, provide surgeons with an improved understanding of their patients' anatomy…
- Trial name
- NCT03870269
- Testing
- Ceevra Reveal
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Ceevra, Inc.
Prostate Cancer
Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
To evaluate activity of gefitinib in subjects with relapsed prostate cancer by estimating PSA response rate at study closure
- Trial name
- NCT00241475
- Testing
- Gefitinib
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Advanced Hormone Dependent Prostate Cancer
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina
- Trial name
- FAST AR (NCT01861236)
- Testing
- Firmagon® (degarelix)
- Where
- Argentina
- Volunteers
- 90 people
- Sponsor
- Ferring Pharmaceuticals
Castrate-Resistant Prostate Cancer
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
This study is designed to assess the safety and tolerability of atezolizumab when given in combination with radium-223 dichloride in participants with metastatic CRPC who have progressed after treatment with an androgen pathway…
- Trial name
- NCT02814669
- Testing
- Atezolizumab, Radium-223 Dichloride
- Where
- 17 sites in United States
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Prostate Cancer, Prostatic Neoplasms
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
- Trial name
- CLARIFY (NCT06056830)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 34 sites in United States, Australia and 1 more
- Volunteers
- 383 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Prostate Cancer
Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform
In this non-interventional study, men being seen by urologists in the course of their normal practice that present with clinical suspicion of prostate cancer (based on DRE, elevated Prostate Specific Antigen (PSA), and/or family…
- Trial name
- NCT04100811
- Where
- 3 sites in United States
- Volunteers
- 2,019 people
- Sponsor
- miR Scientific LLC
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Venous Thromboembolism
Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)
The purpose of this study is to validate the Ottawa score (risk of thromboembolic recurrences) in cancer patients with thromboembolic disease treated with tinzaparin (Innohep®)
- Trial name
- PREDICARE (NCT03099031)
- Testing
- Tinzaparin
- Where
- France
- Volunteers
- 420 people
- Sponsor
- LEO Pharma
Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
- Trial name
- NCT06458712
- Testing
- DSB2455
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 180 people
- Sponsor
- Duke Street Bio Ltd
Prostate Cancer
Clinical Data Collection of Patients Treated With High Intensity Focused Ultrasound (HIFU) by the Focal One for Their Prostate Cancer.
The aim of the registry is to gather real-life data to evaluate the clinical performance and safety of medical devices in patients who have been treated with HIFU thank to the Focal One device for their prostate cancer.
- Trial name
- One registry (NCT07645872)
- Where
- 5 sites in France
- Volunteers
- 3,000 people
- Sponsor
- EDAP TMS S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.